Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) yesterday announced U.S. FDA approval of Clindamycin Injection, USP, an antibiotic used to treat bacterial infections. Sagent Pharmaceuticals' latex-free clindamycin will be available in three single-dose vial sizes and in pharmacy bulk packaging. According to IMS, the 2011 U.S. market for injectable clindamycin approximates $65 million.



Sagent Pharmaceuticals expects to launch the product in early 2012. As with all products in Sagent Pharmaceuticals' portfolio, clindamycin features Sagent Pharmaceuticals' PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors. Clindamycin is the twelfth product approved under the joint venture between Sagent Pharmaceuticals and Strides Arcolab. Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the United States.

Sagent Pharmaceuticals has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.

For more information about Sagent Pharmaceuticals, please visit: www.sagentpharma.com

Read the full article and the disclaimer at: http://drstockpick.com/?p=22319